$691.33
Value $257B
TMO and ZBH stock compared: price, dividend, valuation and results, from SEC filings.
$691.33
Value $257B
$101.41
Value $19.8B
Thermo Fisher Scientific (TMO) has a market value of $257B and Zimmer Biomet (ZBH) $19.8B. Over the last year, with dividends, TMO moved +19.9% and ZBH +14.0%. The P/E is 36.3 for TMO and 25.9 for ZBH. Dividend yield: TMO 0.27%, ZBH 0.95%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
TMO$257B
ZBH$19.8B
TMO is 13 times ZBH
Revenue, 12 months
TMO$47.4B
ZBH$8.6B
TMO is 5.5 times ZBH
Net income, 12 months
TMO$7.1B
ZBH$767M
TMO is 9.2 times ZBH
Operating margin
TMO17.9%
ZBH13.6%
4.3 points apart
ROIC
TMO8.2%
ZBH5.0%
3.2 points apart
P/E
TMO36.3
ZBH25.9
TMO is 1.4 times ZBH
Dividend yield
TMO0.3%
ZBH1.0%
0.7 points apart
5-year return
TMO+10.9%
ZBH-16.8%
27.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
TMO+10.9%
ZBH-16.8%
| Period | TMOWith dividends | ZBHWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +19.9%Price +19.5% | +14.0%Price +12.8% |
| 3 years since November 16, 2023 | +47.7%+13.9% a yearPrice +46.3% | -6.5%-2.2% a yearPrice -9.1% |
| 5 years since November 15, 2021 | +10.9%+2.1% a yearPrice +9.3% | -16.8%-3.6% a yearPrice -20.3% |
| 10 years since November 17, 2016 | +377.7%+16.9% a yearPrice +364.4% | +12.6%+1.2% a yearPrice +3.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
TMOThermo Fisher ScientificZBHZimmer Biomet
| Price | $691.33 | $101.41 |
|---|---|---|
| Market value | $257B | $19.8B |
| Enterprise value (EV) | $292B | $26.9B |
| P/E | 36.3 | 25.9 |
| P/E, 5-year median | 32.7 | 25.1 |
| P/B | 4.7 | 1.6 |
| EV/EBIT | 34.5 | 23.2 |
| Free cash flow yield | 3.0% | 8.3% |
| Revenue, 12 months | $47.4B | $8.6B |
|---|---|---|
| Net income, 12 months | $7.1B | $767M |
| Free cash flow, 12 months | $7.6B | $1.6B |
| Earnings per share, 12 months | $18.96 | $3.96 |
| Revenue growth, year on year | 3.9% | 7.2% |
| Revenue growth a year, past | +6.7%over 5 years | +6.1%over 5 years |
| EPS growth a year, past | +2.1%over 5 years | – |
| Gross margin | – | 69.7% |
|---|---|---|
| Operating margin | 17.9% | 13.6% |
| Net margin | 14.9% | 9.0% |
| ROIC | 8.2% | 5.0% |
| ROE | 13.4% | 6.1% |
| Cash | $6.1B | $400M |
|---|---|---|
| Total debt | $41.4B | $7.5B |
| Net debt / EBITDA | 3.7 | 3.2 |
| Interest cover | 5.5× | – |
| Dividend yield | 0.3% | 1.0% |
|---|---|---|
| Dividend per share, 12 months | $1.84 | $0.96 |
| Dividend growth a year, past | +14.3%over 5 years | +0.0%over 5 years |
| Buyback yield | 1.2% | 2.5% |
| Shareholder yield | 1.4% | 3.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($257B) is about 12.9 times Zimmer Biomet ($19.8B), at today's prices.
Since November 17, 2016, TMO's price moved +364.4% and ZBH's +3.6%. With dividends: TMO +377.7% (+16.9% a year), ZBH +12.6% (+1.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.27% for Thermo Fisher Scientific and 0.95% for Zimmer Biomet. Over the last twelve months they paid $1.84 and $0.96 per share.
At today's price, the P/E is 36.3 for TMO and 25.9 for ZBH. The median of the last five years was 32.7 and 25.1, which shows where each stands against its own past.
Over the last twelve months, the net margin was 14.9% for Thermo Fisher Scientific and 9.0% for Zimmer Biomet, and the operating margin 17.9% and 13.6%. Revenue was $47.4B and $8.6B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.